@article{hui_treatment_2004,
	title = {Treatment of severe acute respiratory syndrome},
	volume = {126},
	issn = {0012-3692},
	url = {http://ovidsp.ovid.com/ovidweb.cgi?T=JS&PAGE=reference&D=emed8&NEWS=N&AN=39258014},
	doi = {10.1378/chest.126.3.670},
	language = {English},
	number = {3},
	journal = {Chest},
	author = {Hui, D. S. C. and Sung, J. J. Y.},
	year = {2004},
	keywords = {*severe acute respiratory syndrome/dt [Drug Therapy], *severe acute respiratory syndrome/ep [Epidemiology], *severe acute respiratory syndrome/th [Therapy], China, SARS coronavirus, SARS coronavirus antibody/dv [Drug Development], Singapore, Taiwan, adult respiratory distress syndrome/co [Complication], adult respiratory distress syndrome/th [Therapy], alpha interferon/dv [Drug Development], alphan1 interferon/dv [Drug Development], alphan3 interferon/dv [Drug Development], aminotransferase blood level, anemia/si [Side Effect], angiotensin receptor, assisted ventilation, bradycardia/si [Side Effect], bronchiolitis/di [Diagnosis], bronchiolitis/dt [Drug Therapy], clinical trial, community acquired pneumonia/th [Therapy], consensus interferon/cb [Drug Combination], consensus interferon/dt [Drug Therapy], corticosteroid/cb [Drug Combination], corticosteroid/dt [Drug Therapy], dipeptidyl carboxypeptidase, editorial, endotracheal intubation, genome analysis, glycyrrhizic acid/dv [Drug Development], health care personnel, helper cell, hemoglobin determination, hemolytic anemia/si [Side Effect], hospital infection, hospitalization, human, human monoclonal antibody, hypoxemia/co [Complication], interferon beta serine/dv [Drug Development], interferon/dt [Drug Therapy], interleukin 1/ec [Endogenous Compound], interleukin 12/ec [Endogenous Compound], interleukin 6/ec [Endogenous Compound], interleukin 8/ec [Endogenous Compound], lopinavir plus ritonavir/cb [Drug Combination], lopinavir plus ritonavir/cm [Drug Comparison], lopinavir plus ritonavir/dt [Drug Therapy], lopinavir/cb [Drug Combination], lopinavir/do [Drug Dose], lopinavir/dt [Drug Therapy], lung injury/pc [Prevention], methylprednisolone/dt [Drug Therapy], methylprednisolone/iv [Intravenous Drug Administration], monocyte chemotactic protein 1/ec [Endogenous Compound], mortality, nonhuman, peginterferon alpha/dt [Drug Therapy], positive end expiratory pressure, priority journal, proteinase, real time polymerase chain reaction, respiratory failure/co [Complication], respiratory failure/th [Therapy], ribavirin/ae [Adverse Drug Reaction], ribavirin/cb [Drug Combination], ribavirin/do [Drug Dose], ribavirin/dt [Drug Therapy], ritonavir/dt [Drug Therapy], serology, severe acute respiratory syndrome vaccine/dt [Drug Therapy], side effect/si [Side Effect], unclassified drug, virus antibody/dv [Drug Development], virus transmission, virus vaccine/dt [Drug Therapy]},
	pages = {670--674},
}

{"_id":"65BeFRs9YS5ECnyb5","bibbaseid":"hui-sung-treatmentofsevereacuterespiratorysyndrome-2004","authorIDs":[],"author_short":["Hui, D. S. C.","Sung, J. J. Y."],"bibdata":{"bibtype":"article","type":"article","title":"Treatment of severe acute respiratory syndrome","volume":"126","issn":"0012-3692","url":"http://ovidsp.ovid.com/ovidweb.cgi?T=JS&PAGE=reference&D=emed8&NEWS=N&AN=39258014","doi":"10.1378/chest.126.3.670","language":"English","number":"3","journal":"Chest","author":[{"propositions":[],"lastnames":["Hui"],"firstnames":["D.","S.","C."],"suffixes":[]},{"propositions":[],"lastnames":["Sung"],"firstnames":["J.","J.","Y."],"suffixes":[]}],"year":"2004","keywords":"*severe acute respiratory syndrome/dt [Drug Therapy], *severe acute respiratory syndrome/ep [Epidemiology], *severe acute respiratory syndrome/th [Therapy], China, SARS coronavirus, SARS coronavirus antibody/dv [Drug Development], Singapore, Taiwan, adult respiratory distress syndrome/co [Complication], adult respiratory distress syndrome/th [Therapy], alpha interferon/dv [Drug Development], alphan1 interferon/dv [Drug Development], alphan3 interferon/dv [Drug Development], aminotransferase blood level, anemia/si [Side Effect], angiotensin receptor, assisted ventilation, bradycardia/si [Side Effect], bronchiolitis/di [Diagnosis], bronchiolitis/dt [Drug Therapy], clinical trial, community acquired pneumonia/th [Therapy], consensus interferon/cb [Drug Combination], consensus interferon/dt [Drug Therapy], corticosteroid/cb [Drug Combination], corticosteroid/dt [Drug Therapy], dipeptidyl carboxypeptidase, editorial, endotracheal intubation, genome analysis, glycyrrhizic acid/dv [Drug Development], health care personnel, helper cell, hemoglobin determination, hemolytic anemia/si [Side Effect], hospital infection, hospitalization, human, human monoclonal antibody, hypoxemia/co [Complication], interferon beta serine/dv [Drug Development], interferon/dt [Drug Therapy], interleukin 1/ec [Endogenous Compound], interleukin 12/ec [Endogenous Compound], interleukin 6/ec [Endogenous Compound], interleukin 8/ec [Endogenous Compound], lopinavir plus ritonavir/cb [Drug Combination], lopinavir plus ritonavir/cm [Drug Comparison], lopinavir plus ritonavir/dt [Drug Therapy], lopinavir/cb [Drug Combination], lopinavir/do [Drug Dose], lopinavir/dt [Drug Therapy], lung injury/pc [Prevention], methylprednisolone/dt [Drug Therapy], methylprednisolone/iv [Intravenous Drug Administration], monocyte chemotactic protein 1/ec [Endogenous Compound], mortality, nonhuman, peginterferon alpha/dt [Drug Therapy], positive end expiratory pressure, priority journal, proteinase, real time polymerase chain reaction, respiratory failure/co [Complication], respiratory failure/th [Therapy], ribavirin/ae [Adverse Drug Reaction], ribavirin/cb [Drug Combination], ribavirin/do [Drug Dose], ribavirin/dt [Drug Therapy], ritonavir/dt [Drug Therapy], serology, severe acute respiratory syndrome vaccine/dt [Drug Therapy], side effect/si [Side Effect], unclassified drug, virus antibody/dv [Drug Development], virus transmission, virus vaccine/dt [Drug Therapy]","pages":"670–674","bibtex":"@article{hui_treatment_2004,\n\ttitle = {Treatment of severe acute respiratory syndrome},\n\tvolume = {126},\n\tissn = {0012-3692},\n\turl = {http://ovidsp.ovid.com/ovidweb.cgi?T=JS&PAGE=reference&D=emed8&NEWS=N&AN=39258014},\n\tdoi = {10.1378/chest.126.3.670},\n\tlanguage = {English},\n\tnumber = {3},\n\tjournal = {Chest},\n\tauthor = {Hui, D. S. C. and Sung, J. J. Y.},\n\tyear = {2004},\n\tkeywords = {*severe acute respiratory syndrome/dt [Drug Therapy], *severe acute respiratory syndrome/ep [Epidemiology], *severe acute respiratory syndrome/th [Therapy], China, SARS coronavirus, SARS coronavirus antibody/dv [Drug Development], Singapore, Taiwan, adult respiratory distress syndrome/co [Complication], adult respiratory distress syndrome/th [Therapy], alpha interferon/dv [Drug Development], alphan1 interferon/dv [Drug Development], alphan3 interferon/dv [Drug Development], aminotransferase blood level, anemia/si [Side Effect], angiotensin receptor, assisted ventilation, bradycardia/si [Side Effect], bronchiolitis/di [Diagnosis], bronchiolitis/dt [Drug Therapy], clinical trial, community acquired pneumonia/th [Therapy], consensus interferon/cb [Drug Combination], consensus interferon/dt [Drug Therapy], corticosteroid/cb [Drug Combination], corticosteroid/dt [Drug Therapy], dipeptidyl carboxypeptidase, editorial, endotracheal intubation, genome analysis, glycyrrhizic acid/dv [Drug Development], health care personnel, helper cell, hemoglobin determination, hemolytic anemia/si [Side Effect], hospital infection, hospitalization, human, human monoclonal antibody, hypoxemia/co [Complication], interferon beta serine/dv [Drug Development], interferon/dt [Drug Therapy], interleukin 1/ec [Endogenous Compound], interleukin 12/ec [Endogenous Compound], interleukin 6/ec [Endogenous Compound], interleukin 8/ec [Endogenous Compound], lopinavir plus ritonavir/cb [Drug Combination], lopinavir plus ritonavir/cm [Drug Comparison], lopinavir plus ritonavir/dt [Drug Therapy], lopinavir/cb [Drug Combination], lopinavir/do [Drug Dose], lopinavir/dt [Drug Therapy], lung injury/pc [Prevention], methylprednisolone/dt [Drug Therapy], methylprednisolone/iv [Intravenous Drug Administration], monocyte chemotactic protein 1/ec [Endogenous Compound], mortality, nonhuman, peginterferon alpha/dt [Drug Therapy], positive end expiratory pressure, priority journal, proteinase, real time polymerase chain reaction, respiratory failure/co [Complication], respiratory failure/th [Therapy], ribavirin/ae [Adverse Drug Reaction], ribavirin/cb [Drug Combination], ribavirin/do [Drug Dose], ribavirin/dt [Drug Therapy], ritonavir/dt [Drug Therapy], serology, severe acute respiratory syndrome vaccine/dt [Drug Therapy], side effect/si [Side Effect], unclassified drug, virus antibody/dv [Drug Development], virus transmission, virus vaccine/dt [Drug Therapy]},\n\tpages = {670--674},\n}\n\n","author_short":["Hui, D. S. C.","Sung, J. J. Y."],"key":"hui_treatment_2004","id":"hui_treatment_2004","bibbaseid":"hui-sung-treatmentofsevereacuterespiratorysyndrome-2004","role":"author","urls":{"Paper":"http://ovidsp.ovid.com/ovidweb.cgi?T=JS&PAGE=reference&D=emed8&NEWS=N&AN=39258014"},"keyword":["*severe acute respiratory syndrome/dt [Drug Therapy]","*severe acute respiratory syndrome/ep [Epidemiology]","*severe acute respiratory syndrome/th [Therapy]","China","SARS coronavirus","SARS coronavirus antibody/dv [Drug Development]","Singapore","Taiwan","adult respiratory distress syndrome/co [Complication]","adult respiratory distress syndrome/th [Therapy]","alpha interferon/dv [Drug Development]","alphan1 interferon/dv [Drug Development]","alphan3 interferon/dv [Drug Development]","aminotransferase blood level","anemia/si [Side Effect]","angiotensin receptor","assisted ventilation","bradycardia/si [Side Effect]","bronchiolitis/di [Diagnosis]","bronchiolitis/dt [Drug Therapy]","clinical trial","community acquired pneumonia/th [Therapy]","consensus interferon/cb [Drug Combination]","consensus interferon/dt [Drug Therapy]","corticosteroid/cb [Drug Combination]","corticosteroid/dt [Drug Therapy]","dipeptidyl carboxypeptidase","editorial","endotracheal intubation","genome analysis","glycyrrhizic acid/dv [Drug Development]","health care personnel","helper cell","hemoglobin determination","hemolytic anemia/si [Side Effect]","hospital infection","hospitalization","human","human monoclonal antibody","hypoxemia/co [Complication]","interferon beta serine/dv [Drug Development]","interferon/dt [Drug Therapy]","interleukin 1/ec [Endogenous Compound]","interleukin 12/ec [Endogenous Compound]","interleukin 6/ec [Endogenous Compound]","interleukin 8/ec [Endogenous Compound]","lopinavir plus ritonavir/cb [Drug Combination]","lopinavir plus ritonavir/cm [Drug Comparison]","lopinavir plus ritonavir/dt [Drug Therapy]","lopinavir/cb [Drug Combination]","lopinavir/do [Drug Dose]","lopinavir/dt [Drug Therapy]","lung injury/pc [Prevention]","methylprednisolone/dt [Drug Therapy]","methylprednisolone/iv [Intravenous Drug Administration]","monocyte chemotactic protein 1/ec [Endogenous Compound]","mortality","nonhuman","peginterferon alpha/dt [Drug Therapy]","positive end expiratory pressure","priority journal","proteinase","real time polymerase chain reaction","respiratory failure/co [Complication]","respiratory failure/th [Therapy]","ribavirin/ae [Adverse Drug Reaction]","ribavirin/cb [Drug Combination]","ribavirin/do [Drug Dose]","ribavirin/dt [Drug Therapy]","ritonavir/dt [Drug Therapy]","serology","severe acute respiratory syndrome vaccine/dt [Drug Therapy]","side effect/si [Side Effect]","unclassified drug","virus antibody/dv [Drug Development]","virus transmission","virus vaccine/dt [Drug Therapy]"],"metadata":{"authorlinks":{}}},"bibtype":"article","biburl":"https://bibbase.org/zotero/vincentwntu","creationDate":"2020-01-26T03:06:33.954Z","downloads":0,"keywords":["*severe acute respiratory syndrome/dt [drug therapy]","*severe acute respiratory syndrome/ep [epidemiology]","*severe acute respiratory syndrome/th [therapy]","china","sars coronavirus","sars coronavirus antibody/dv [drug development]","singapore","taiwan","adult respiratory distress syndrome/co [complication]","adult respiratory distress syndrome/th [therapy]","alpha interferon/dv [drug development]","alphan1 interferon/dv [drug development]","alphan3 interferon/dv [drug development]","aminotransferase blood level","anemia/si [side effect]","angiotensin receptor","assisted ventilation","bradycardia/si [side effect]","bronchiolitis/di [diagnosis]","bronchiolitis/dt [drug therapy]","clinical trial","community acquired pneumonia/th [therapy]","consensus interferon/cb [drug combination]","consensus interferon/dt [drug therapy]","corticosteroid/cb [drug combination]","corticosteroid/dt [drug therapy]","dipeptidyl carboxypeptidase","editorial","endotracheal intubation","genome analysis","glycyrrhizic acid/dv [drug development]","health care personnel","helper cell","hemoglobin determination","hemolytic anemia/si [side effect]","hospital infection","hospitalization","human","human monoclonal antibody","hypoxemia/co [complication]","interferon beta serine/dv [drug development]","interferon/dt [drug therapy]","interleukin 1/ec [endogenous compound]","interleukin 12/ec [endogenous compound]","interleukin 6/ec [endogenous compound]","interleukin 8/ec [endogenous compound]","lopinavir plus ritonavir/cb [drug combination]","lopinavir plus ritonavir/cm [drug comparison]","lopinavir plus ritonavir/dt [drug therapy]","lopinavir/cb [drug combination]","lopinavir/do [drug dose]","lopinavir/dt [drug therapy]","lung injury/pc [prevention]","methylprednisolone/dt [drug therapy]","methylprednisolone/iv [intravenous drug administration]","monocyte chemotactic protein 1/ec [endogenous compound]","mortality","nonhuman","peginterferon alpha/dt [drug therapy]","positive end expiratory pressure","priority journal","proteinase","real time polymerase chain reaction","respiratory failure/co [complication]","respiratory failure/th [therapy]","ribavirin/ae [adverse drug reaction]","ribavirin/cb [drug combination]","ribavirin/do [drug dose]","ribavirin/dt [drug therapy]","ritonavir/dt [drug therapy]","serology","severe acute respiratory syndrome vaccine/dt [drug therapy]","side effect/si [side effect]","unclassified drug","virus antibody/dv [drug development]","virus transmission","virus vaccine/dt [drug therapy]"],"search_terms":["treatment","severe","acute","respiratory","syndrome","hui","sung"],"title":"Treatment of severe acute respiratory syndrome","year":2004,"dataSources":["icTw8KRRMMANXJHRd"]}